STRATEC raises sales and earnings forecast for 2008 to 2010

9/7/2006, 11:15 AM (Source: GlobeNewswire)
Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------



Birkenfeld, September 7, 2006

STRATEC Biomedical Systems AG today published an ad-hoc announcement
(statutory company announcement) with its sales and earnings forecast
for the 2006 and 2007 financial years. Pursuant to this announcement,
the company assumes that it will be possible to increase its sales
for 2006 to between Euro 65 million and Euro 68 million (sales
corridor) and for 2007 to between Euro 75 million and Euro 78 million
(sales corridor) and to increase its earnings before tax (EBT) to
between Euro 10.5 million and Euro 11 million in 2006 (earnings
corridor) and to between Euro 14 million and Euro 15 million in 2007
(earnings corridor).

In view of the considerable increase in the basis for the 2007
financial year, based on its current planning the company expects to
achieve an annual average growth rate (CAGR) of more than 11% in the
case of sales and of more than 16% for earnings before tax (EBT) from
2008 up to and including 2010.

As a result of the basis effect (higher basis in 2007) and the
shifting of the period under consideration by one year from 2008 the
average annual growth rate (CAGR) for our key sales and earnings
figures is lower in percentage terms, yet higher in absolute terms,
in the long-term forecast (for 2008 to 2010) than in the forecast
published in December 2005 (for 2007 to 2009). Assuming that the
targets stated in our long-term forecast are met, the average annual
growth rate (CAGR) reported by the STRATEC Group for the financial
years from 2000 to 2010 would amount to more than 25% in the case of
sales and to more than 34% in the case of earnings before tax (EBT).

The forecast for 2008 to 2010 takes only limited account of the
conclusion of outstanding new development and supply agreements for
new analyzer system families with existing and new customers.

The new budget figures are considerably higher than the internal
budget targets most recently forecast in December 2005. These
forecast that the sales for the 2006 financial year would increase to
Euro 55 million to Euro 59 million (sales corridor) and that earnings
before tax (EBT) would rise to Euro 8.3 million to Euro 9.2 million
(earnings corridor). An average annual growth rate (CAGR) of more
than 15% in the case of sales and of more than 22% for earnings
before tax (EBT) was forecast for the subsequent 2007 to 2009
financial years.

The annual average growth (CAGR) reported for the financial years
from 2000 up to and including 2005 amounted to more than 32% in terms
of sales and to more than 40% in the case of earnings before tax
(EBT).


About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de)
designs and manufactures fully automated systems for its partners in
the fields of clinical diagnostics and biotechnology. These partners
market such systems, in general together with their own reagents, to
laboratories and research institutes around the world. The company
develops its products on the basis of its own patented technologies.
Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded
in the Prime Standard segment of the Frankfurt Stock Exchange, in the
Gate-M trading segment of the Stuttgart Stock Exchange and on other
exchanges.

The STRATEC Group comprises the listed holding company "STRATEC
Biomedical Systems AG", as well as the subsidiaries "STRATEC NewGen",
"Robion" and "Sanguin".


Further information can be obtained from:

STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestrasse 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
E-Mail: ir@stratec-biomedical.de



--- End of Message ---
WKN: 728900; ISIN: DE0007289001;
Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Gate-M in
Börse Stuttgart,
Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse
München,
Freiverkehr in Börse Düsseldorf;
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.